Quick Answer
TransMedics Group, Inc. reported Operating Income Loss of $108.58 million for the year ending 2025.
- TransMedics Group, Inc. showed an increase of +189.6% in Operating Income Loss from 2024 to 2025.
- This data is from TransMedics Group, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$4.78 million | Q2 2018: -$5.16 million | Q3 2018: -$3.94 million | Q4 2018: -$6.36 million | Q1 2019: -$5.96 million | Q2 2019: -$7.71 million | Q3 2019: -$7.24 million | Q4 2019: -$8.69 million | Q1 2020: -$8.02 million | Q2 2020: -$7.86 million | Q3 2020: -$4.61 million | Q4 2020: -$5.90 million | Q1 2021: -$6.51 million | Q2 2021: -$9.87 million | Q3 2021: -$11.73 million | Q1 2022: -$9.37 million | Q2 2022: -$9.75 million | Q3 2022: -$5.54 million | Q1 2023: -$2.09 million | Q2 2023: -$906.0 thousand | Q3 2023: -$28.34 million | Q1 2024: $12.42 million | Q2 2024: $12.51 million | Q3 2024: $3.92 million | Q1 2025: $27.44 million | Q2 2025: $36.57 million | Q3 2025: $23.30 million.
- Over the full 8 years of available data (2018 to 2025), TransMedics Group, Inc.'s Operating Income Loss has grown by 636.6%.
- Historical annual values: Fiscal year 2025: $108.58 million | Fiscal year 2024: $37.50 million | Fiscal year 2023: -$28.73 million | Fiscal year 2022: -$31.44 million | Fiscal year 2021: -$39.43 million | Fiscal year 2020: -$26.38 million | Fiscal year 2019: -$29.60 million | Fiscal year 2018: -$20.24 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: